Cdi 10:1 Us Prohib Excl Qib Deferred Settlement (EBRDA) - Net Assets
Based on the latest financial reports, Cdi 10:1 Us Prohib Excl Qib Deferred Settlement (EBRDA) has net assets worth AU$25.59 Million AUD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$97.23 Million) and total liabilities (AU$71.64 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$25.59 Million |
| % of Total Assets | 26.32% |
| Annual Growth Rate | -9.22% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 13.32 |
Cdi 10:1 Us Prohib Excl Qib Deferred Settlement - Net Assets Trend (2023–2025)
This chart illustrates how Cdi 10:1 Us Prohib Excl Qib Deferred Settlement's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Cdi 10:1 Us Prohib Excl Qib Deferred Settlement (2023–2025)
The table below shows the annual net assets of Cdi 10:1 Us Prohib Excl Qib Deferred Settlement from 2023 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | AU$25.59 Million | +5.06% |
| 2024-12-31 | AU$24.36 Million | -21.58% |
| 2023-12-31 | AU$31.06 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cdi 10:1 Us Prohib Excl Qib Deferred Settlement's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8955659000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$45.00K | 0.18% |
| Other Components | AU$427.76 Million | 1671.72% |
| Total Equity | AU$25.59 Million | 100.00% |
Cdi 10:1 Us Prohib Excl Qib Deferred Settlement Competitors by Market Cap
The table below lists competitors of Cdi 10:1 Us Prohib Excl Qib Deferred Settlement ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Miton UK MicroCap Trust PLC
LSE:MINI
|
$47.43 |
|
Fantasy Network Ltd
TA:FNTS
|
$47.45 |
|
Man Shing Agricultural Holdings Inc
PINK:MSAH
|
$47.48 |
|
Petrovietnam Pac
VN:PBP
|
$47.49 |
|
Cuulong Fish JSC
VN:ACL
|
$47.30 |
|
National Silk and Rayon Mills Limited
KAR:NSRM
|
$47.30 |
|
MEGA AFRICAN CAPITAL LIMITED
GSE:MAC
|
$47.29 |
|
Canyon Bancorp
PINK:CYBA
|
$47.24 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cdi 10:1 Us Prohib Excl Qib Deferred Settlement's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 24,355,500 to 25,588,000, a change of 1,232,500 (5.1%).
- Net loss of 48,758,000 reduced equity.
- Share repurchases of 49,475,000 reduced equity.
- Other factors increased equity by 99,465,500.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-48.76 Million | -190.55% |
| Share Repurchases | AU$49.48 Million | -193.35% |
| Other Changes | AU$99.47 Million | +388.72% |
| Total Change | AU$- | 5.06% |
Book Value vs Market Value Analysis
This analysis compares Cdi 10:1 Us Prohib Excl Qib Deferred Settlement's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 11.79x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 6.67x to 11.79x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2023-12-31 | AU$0.10 | AU$0.67 | x |
| 2024-12-31 | AU$0.07 | AU$0.67 | x |
| 2025-12-31 | AU$0.06 | AU$0.67 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cdi 10:1 Us Prohib Excl Qib Deferred Settlement utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -190.55%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3015.34%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 3.80x
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2025 | -190.55% | -3015.34% | 0.02x | 3.80x | AU$-51.32 Million |
Industry Comparison
This section compares Cdi 10:1 Us Prohib Excl Qib Deferred Settlement's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cdi 10:1 Us Prohib Excl Qib Deferred Settlement (EBRDA) | AU$25.59 Million | -190.55% | 2.80x | $47.41 |
| PATRYS Ltd (PAB) | $22.98 Million | -31.88% | 0.04x | $6.03 Million |
| Perpetual Credit Income Trust (PCI) | $532.80 Million | 7.05% | 0.01x | $314.92 Million |
| Regal Investment Fund (RF1) | $287.59 Million | 2.02% | 0.78x | $480.04 Million |
| Regal Partners Global Investments Limited (RG1) | $731.12 Million | -26.38% | 0.53x | $166.28 |
| Rivco Australia Ltd (RIV) | $195.76 Million | 4.77% | 0.60x | $103.30 |
| Touch Ventures Ltd (TVL) | $60.18 Million | -5.66% | 0.01x | $35.33 Million |
| Vgi Partners Global Investments Ltd (VG1) | $583.71 Million | 5.68% | 0.31x | $716.93 Million |
| Victory Metals Ltd (VTM) | $-46.39K | 0.00% | 0.00x | $17.50 Million |
About Cdi 10:1 Us Prohib Excl Qib Deferred Settlement
EBR Systems, Inc. develops implantable systems for wireless tissue stimulation. It offers WiSE cardiac resynchronization therapy system, an implantable cardiac pacing system able to provide stimulation to endocardial heart tissue for the correction of heart rhythm conditions without requiring the use of leads; and stimulation of the left ventricular endocardium for cardiac resynchronization thera… Read more